TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 12, 2024
TEVA$42.40-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of comprehensive income (loss)
| Year ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net income (loss) | $(615) | $(2,499) | $456 |
| Other comprehensive income (loss), net of tax: | |||
| Currency translation adjustment | 80 | (356) | (462) |
| Unrealized gain (loss) on derivative financial instruments, net | 29 | 29 | 39 |
| Unrealized gain (loss) on defined benefit plans, net | (18) | 57 | 32 |
| Total other comprehensive income (loss) | 91 | (270) | (391) |
| Total comprehensive income (loss) | (524) | (2,769) | 65 |
| Comprehensive income (loss) attributable to non-controlling interests | (106) | (169) | (68) |
| Comprehensive income (loss) attributable to Teva | $(418) | $(2,600) | $133 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.